Rasagiline Mesylate [clinicaltrials_resource:NCT00977665/group/B1]
rasagiline tablet, 1 mg/day for up to 48 weeks.
group [clinicaltrials_vocabulary:group]
NCT00977665 measurement [clinicaltrials_resource:NCT00977665/measurement/0208cb524ed872b5924e7a76b77d1a27]NCT00977665 measurement [clinicaltrials_resource:NCT00977665/measurement/154d7ad3f60df633fc42f40b08e56bc8]NCT00977665 measurement [clinicaltrials_resource:NCT00977665/measurement/24ae7a69312b951e472a6149f9a61bd5]NCT00977665 measurement [clinicaltrials_resource:NCT00977665/measurement/2755cc8cda4f402e96bb2093df48d1bb]NCT00977665 measurement [clinicaltrials_resource:NCT00977665/measurement/28cac9e048a5ab701b70797333fef96d]NCT00977665 measurement [clinicaltrials_resource:NCT00977665/measurement/2a6b6d70c9be31d9a17dcdb765360ad8]NCT00977665 measurement [clinicaltrials_resource:NCT00977665/measurement/33306658ab75fd8d739bf5a79ade6be4]NCT00977665 measurement [clinicaltrials_resource:NCT00977665/measurement/37c9a550170a1c86d4a55aa154736413]NCT00977665 measurement [clinicaltrials_resource:NCT00977665/measurement/37cc25ac0d4a2ee2ea3923d95c160129]NCT00977665 measurement [clinicaltrials_resource:NCT00977665/measurement/4b4bb7e15669d297f6874e0135caf2aa]NCT00977665 measurement [clinicaltrials_resource:NCT00977665/measurement/74dcb3775e645e7418468d00f0965b59]NCT00977665 measurement [clinicaltrials_resource:NCT00977665/measurement/752f64c3edc175bbd68ff6d11d0d2057]NCT00977665 measurement [clinicaltrials_resource:NCT00977665/measurement/79eb56590ff77b065dd8bbdc7ba0ffbf]NCT00977665 measurement [clinicaltrials_resource:NCT00977665/measurement/7a79171e9e9718cb7e4f24e7c557dd9d]NCT00977665 measurement [clinicaltrials_resource:NCT00977665/measurement/8026d64010b5eb5f265916f8ba81eb23]NCT00977665 measurement [clinicaltrials_resource:NCT00977665/measurement/876f2029ad15d89b34dd6a88f90c88cc]NCT00977665 measurement [clinicaltrials_resource:NCT00977665/measurement/8b8a5ec7e4f316a301edc91e8887967d]NCT00977665 measurement [clinicaltrials_resource:NCT00977665/measurement/a785cc88078f32ae8ea1b0f005866253]NCT00977665 measurement [clinicaltrials_resource:NCT00977665/measurement/b7826f979c3c31402736bf43b16a1a49]NCT00977665 measurement [clinicaltrials_resource:NCT00977665/measurement/cbf90cbec07e9a5cad3c8d4bfde2907d]NCT00977665 measurement [clinicaltrials_resource:NCT00977665/measurement/f59ffd064e6ca0fa058f91363e68086c]
group id [clinicaltrials_vocabulary:group-id]
Rasagiline Mesylate [clinicaltrials_resource:NCT00977665/group/B1]
rasagiline tablet, 1 mg/day for up to 48 weeks.
Bio2RDF identifier
NCT00977665/group/B1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00977665/group/B1
group id [clinicaltrials_vocabulary:group-id]
description
rasagiline tablet, 1 mg/day for up to 48 weeks.
@en
identifier
clinicaltrials_resource:NCT00977665/group/B1
title
Rasagiline Mesylate
@en
type
label
Rasagiline Mesylate [clinicaltrials_resource:NCT00977665/group/B1]
@en